Tai Han - SciVision Biotech Gen Director

All Insiders . Taiwan . 
Stock . SciVision Biotech . Stakeholders . Insider . Tai Han
1786 Stock  TWD 91.70  1.00  1.10%   

Insider

Tai Han is Gen Director of SciVision Biotech
Phone886 7 823 2258
Webhttps://www.scivision.com.tw

SciVision Biotech Management Efficiency

The company has return on total asset (ROA) of 0.0331 % which means that it generated a profit of $0.0331 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0952 %, meaning that it generated $0.0952 on every $100 dollars invested by stockholders. SciVision Biotech's management efficiency ratios could be used to measure how well SciVision Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
SciVision Biotech has accumulated 300 M in total debt with debt to equity ratio (D/E) of 22.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SciVision Biotech has a current ratio of 4.03, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist SciVision Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, SciVision Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciVision Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciVision to invest in growth at high rates of return. When we think about SciVision Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

James ChuApex Biotechnology Corp
N/A
JunJie LiaoChunghwa Chemical Synthesis
N/A
ChaoSheng HongChunghwa Chemical Synthesis
N/A
ChungHsin HuangChunghwa Chemical Synthesis
N/A
BS MSScinoPharm Taiwan
N/A
ChingTing ChenMaxigen Biotech
N/A
Shun LinScinoPharm Taiwan
N/A
Ben ShenApex Biotechnology Corp
N/A
WanHow YouMaxigen Biotech
N/A
LiChiao ChemistryScinoPharm Taiwan
N/A
Jason ChenScinoPharm Taiwan
N/A
KuanChieh WangChunghwa Chemical Synthesis
N/A
Chun WuApex Biotechnology Corp
N/A
Thomas ShenApex Biotechnology Corp
N/A
Meng YangApex Biotechnology Corp
N/A
Ying ZhuApex Biotechnology Corp
N/A
ChihHui LinScinoPharm Taiwan
N/A
PoHung LaiMaxigen Biotech
N/A
LingHsiao LienScinoPharm Taiwan
N/A
Li XieSinphar Pharmaceutical Co
N/A
Karen LeeMaxigen Biotech
N/A
SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. SciVision Biotech Inc.was founded in 2001 and is based in Kaohsiung, Taiwan. SCIVISION BIOTECH operates under Medical Instruments Supplies classification in Taiwan and is traded on Taiwan Stock Exchange. SciVision Biotech (1786) is traded on Taiwan Stock Exchange in Taiwan and employs 11 people.

Management Performance

Return On Equity0.0952
Return On Asset0.0331

SciVision Biotech Leadership Team

Elected by the shareholders, the SciVision Biotech's board of directors comprises two types of representatives: SciVision Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciVision. The board's role is to monitor SciVision Biotech's management team and ensure that shareholders' interests are well served. SciVision Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciVision Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tai Han, Gen Director
Ru Guo, Financial VP

SciVision Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciVision Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0952
Return On Asset0.0331
Profit Margin0.26 %
Operating Margin0.23 %
Current Valuation3.06 B
Shares Outstanding66.19 M
Shares Owned By Insiders38.09 %
Shares Owned By Institutions0.09 %
Price To Earning46.92 X
Price To Book2.47 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for SciVision Stock Analysis

When running SciVision Biotech's price analysis, check to measure SciVision Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SciVision Biotech is operating at the current time. Most of SciVision Biotech's value examination focuses on studying past and present price action to predict the probability of SciVision Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SciVision Biotech's price. Additionally, you may evaluate how the addition of SciVision Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY